Q-omics provides the consensus-scored FOXO6 profile across patient tissues and cancer cell-line models. FOXO6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FOXO6 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, FOXO6 RNA expression shows 15,797 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight UCEC, KICH, and SARC as cancer lineages where FOXO6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXO6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXO6 survival associations across molecular data types. FOXO6 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXO6 RNA expression–survival associations across cancer types. High FOXO6 expression shows unfavorable associations in UCEC, KIRP and UVM, but favorable associations in LUAD, LGG and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for FOXO6 RNA expression.
This table summarizes FOXO6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FOXO6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXO6 shows lower tumor expression in KICH and THCA and higher tumor expression in LUAD, BRCA, LIHC and LUSC. The KICH box plot shows higher FOXO6 RNA expression in normal versus tumor tissue (log2 FC = −1.382, t-test p < 0.001).
This table shows molecular features associated with FOXO6 in patient tissues and cancer cell lines. In patient samples, FOXO6 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXO6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and URINARY_TRACT.
